ArticleJournal of hematology & oncology2021
Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL.
Open access · goldAbstract read
In one paragraph
Article in Journal of hematology & oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Clinicopathological and prognostic significance of DDX41 mutation in myeloid neoplasms: a systematic review and meta-analysis.Annals of hematology · 2025Pooled it
- A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.Nature reviews. Cancer · 2026Review
- The machine-learning classifier ALLCatchR2 identifies 20 T-ALL subtypes across cohorts and age groups.HemaSphere · 2026Article
- Mutations in isocitrate dehydrogenase portend a poor prognosis in adult patients with acute lymphoblastic leukemia.Blood advances · 2026Article
- Therapeutic targeting of chromatin alterations in leukemia and solid tumors.International journal of cancer · 2026Review
- Case Report: Early T-cell precursor acute lymphoblastic leukemia with aberrant CD19 expression and anFrontiers in oncology · 2026Article
- Single-Cell Multiomics Reveals TCR Clonotype-Specific Phenotype and Stemness Heterogeneity of T-ALL Cells.Cell proliferation · 2025Article
- Neomorphic IDH Heterodimer Mutants: An Underestimated Point in Cancer Pathogenesis.Current cancer drug targets · 2025Review
- The Need to Set up a Biobank Dedicated to Lymphoid Malignancies: Experience of a Single Center (Laboratory of Clinical and Experimental Pathology, University Côte d'Azur, Nice, France).Journal of personalized medicine · 2023Article
- TNFAIP3 mutation is an independent poor overall survival factor for patients with T-cell acute lymphoblastic leukemia.Cancer medicine · 2023Article
- NovelMediterranean journal of hematology and infectious diseases · 2023Article
- Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool.International journal of molecular sciences · 2022Review
- A murine model for human early/immature T-cell precursor acute lymphoblastic leukemia (EITP ALL).Oncoscience · 2022Article
- Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia.Genes · 2021Article
- MutantCancer research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 15 institutions in 2 countries.
Mathieu SimoninLaboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Université de Paris, 149 rue de Sèvres, 75015, Paris, France.
Aline SchmidtPRES LUNAM, CHU Angers service des Maladies du Sang, INSERM U 892, Angers, France.
Christophe BontouxLaboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Université de Paris, 149 rue de Sèvres, 75015, Paris, France.
Marie-Émilie DourtheLaboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Université de Paris, 149 rue de Sèvres, 75015, Paris, France.
Etienne LenglinéUniversité Paris Diderot, Institut Universitaire d'Hématologie, EA-3518, Assistance Publique-Hôpitaux de Paris, University Hospital Saint-Louis, Paris, France.
Guillaume P AndrieuLaboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Université de Paris, 149 rue de Sèvres, 75015, Paris, France.
Ludovic LhermitteLaboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Université de Paris, 149 rue de Sèvres, 75015, Paris, France.
Carlos GrauxDepartment of Hematology, Université Catholique de Louvain, CHU UCL Namur - site Godinne, Yvoir, Belgium.
Nathalie GrardelLaboratory of Hematology, CHRU - Inserm U1172, Lille, France.
Jean-Michel CayuelaLaboratory of Hematology, Saint-Louis Hospital, AP-HP, Paris, France.
Françoise HuguetDepartment of Hematology, CHRU - Institut Universitaire de Cancer Toulouse - Oncopole, Toulouse, France.
Isabelle ArnouxLaboratory of Hematology, Marseille University Hospital Timone, Marseille, France.
Stéphane DucassouPediatric Hematology-Oncology Department, Centre Hospitalier Universitaire (CHU), Bordeaux, France.
Elizabeth MacintyreLaboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Université de Paris, 149 rue de Sèvres, 75015, Paris, France.
Virginie GandemerDepartment of Pediatric Hematology and Oncology, University Hospital of Rennes, Rennes, France.
Hervé DombretUniversité Paris Diderot, Institut Universitaire d'Hématologie, EA-3518, Assistance Publique-Hôpitaux de Paris, University Hospital Saint-Louis, Paris, France.
Arnaud PetitDepartment of Pediatric Hematology and Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Armand Trousseau Hospital, Sorbonne Université, Paris, France.
Norbert IfrahPRES LUNAM, CHU Angers service des Maladies du Sang, INSERM U 892, Angers, France.
André BaruchelDepartment of Pediatric Hematology and Immunology, Assistance Publique-Hôpitaux de Paris (AP-HP), Robert Debré Hospital, University Paris Diderot, Paris, France.
Nicolas BoisselUniversité Paris Diderot, Institut Universitaire d'Hématologie, EA-3518, Assistance Publique-Hôpitaux de Paris, University Hospital Saint-Louis, Paris, France.
Vahid AsnafiLaboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Université de Paris, 149 rue de Sèvres, 75015, Paris, France. vahid.asnafi@aphp.fr.
Université Paris Cité · FRHôpital Necker-Enfants Malades · FRHôpital Saint-Louis · FRInserm · FRInstitut Necker Enfants Malades · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Universitaire de Bordeaux · FRCentre Hospitalier Universitaire de Lille · FRCentre Hospitalier Universitaire de Rennes · FRDélégation Paris 7 · FRHôpital de la Timone · FRHôpital Robert-Debré · FRInstitut universitaire du cancer de Toulouse Oncopole · FRSorbonne Université · FRUCLouvain · BE
Funding
No grant is acknowledged in the PubMed record.
Abstract
IDH1 and IDH2 mutations (IDH1/2
Indexed as
AdolescentAdultChildChild, PreschoolHumansIsocitrate DehydrogenaseMiddle AgedMutationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaPrognosisYoung AdultIDH1 protein, humanIDH2 protein, humanIsocitrate DehydrogenaseIDH1IDH2T-ALL
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.